Telomir Pharmaceuticals (TELO) said Wednesday it has obtained $3 million in equity financing through a direct investment from its largest shareholder The Bayshore Trust.
The deal, which involved the purchase of 1 million Telomir restricted shares at $3 apiece, was structured as a straight stock transaction with no warrants, discounts, and convertible features, the company said.
Telomir said the investment will fund its upcoming submission of its investigational new drug application for a rare disease indication.
Shares of the company fell 3.1% in recent trading.
Price: 2.22, Change: -0.07, Percent Change: -3.10
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。